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 EDITORIAL AUTHOR’S VIEW
Introduction
Soft tissue sarcomas (STS) are relatively 
rare, heterogeneous malignancies of mes-
enchymal origin with a high mortality 
rate. They comprise less than 1% of adult 
malignancies and approximately 50% of 
the STS patients will succumb to their dis-
ease because of metastasis or local relapse. 
There are several prognostic factors which 
determine tumor progression, and ulti-
mately the patient’s outcome, including 
positive resection margins; presence of 
local recurrence; and tumor grade, size, 
location, depth and histological entity. 
The purpose of this study1 was to clarify 
the prognostic significance of lymphocyte 
infiltration in non-gastrointestinal stro-
mal tumor (GIST) STSs.
Results
Clinicopathological variables. Patient age 
range was 0–91 years (mean 55 years), 
and 44% of the patients were males. The 
non-GIST STS comprised 68 undifferen-
tiated pleomorphic sarcoma, 67 leiomyo-
sarcoma, 34 liposarcoma, 20 malignant 
fibroblastic/myofibroblastic tumors, 16 
rhabdomyosarcoma, 16 synovial sarcoma, 
13 angiosarcoma, 11 malignant periph-
eral nerve sheath tumors (MPNST) and 4 
other STS. There were 61 low grade STS 
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(24%) and 188 high grade (FNCLCC 
grade 2 and 3) STS (76%).
The treatment option of choice was sur-
gery (n = 228): 118 patients received sur-
gery only; 55 patients received surgery and 
radiotherapy; 40 patients received surgery 
and chemotherapy; 13 patients received 
surgery, radiotherapy and chemotherapy; 
2 patients received chemotherapy only; 3 
patients received chemotherapy and radio-
therapy; 2 patients received radiotherapy 
only; and 16 patients received no therapy. 
The 5-year survival with non-wide resec-
tion margins was 33% and with wide 
resection margins it was 62%.
Univariate analyses. Nationality, 
tumor size, malignancy grade, tumor 
depth, metastasis at time of diagnosis, 
surgery and surgical margins were all sig-
nificant indicators for disease-specific sur-
vival (DSS) in univariate analyses. Most 
of the patients with non-GIST STS who 
did not survive their disease, died within 
the first 10 years (120 months). After 10 
years almost 60% (n = 108) of the patients 
with wide resection margins were alive, 
but only 20% (n = 141) of patients with 
non-wide resection margins or no surgery 
(p < 0.001).
Furthermore, increasing numbers of 
CD4+ (p = 0.008) and CD20+ lymphocytes 
in tumor (p = 0.006) correlated signifi-
cantly with an improved DSS in patients 
with wide resection margins (n = 108) 
Figure 1. In patients with non-wide resec-
tion margins (n = 141) increasing numbers 
of CD3+ lymphocytes correlated signifi-
cantly (p = 0.028) with shorter DSS.
Multivariate analyses. An independent 
positive prognostic factor for improved 
DSS in patients with wide resection mar-
gin was a high number of CD20+ lym-
phocytes in the tumor (HR 5.5, CI 95% 
1.62–18.61, p = 0.006).
Discussion
Activation of the adaptive immune system 
may suppress malignant cells, whereas acti-
vation of various types of innate immune 
cells may promote tumor growth.3 The 
adaptive immunity, orchestrated by anti-
gen-specific T and B-lymphocytes, inhib-
its tumor growth through both direct 
killing by cytotoxic T-lymphocytes, and 
a combination of cytokine and antibody 
mediated tumor cell lysis.3 Cancer infil-
tration by tumor reactive T-lymphocytes 
is required for efficient tumor eradica-
tion.4 However, cancer cells can escape the 
immune system in several ways includ-
ing suppression of cytotoxic T-cells, by 
regulatory T-cells and by accumulation of 
myeloid suppressor cells.4
The role of CD4+ T and B lympho-
cytes is controversial in many cancers 
The immune status is important in cancer patients. Tissue microarrays from 249 patients with soft tissue sarcomas were 
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mediating a strong anti-tumor immune 
response in STS, but this effect is not 
strong enough to improve survival in 
patients without wide resection margins.
Among STS patients who have had 
wide resection margins, it will be essen-
tial to identify those who will relapse 
and succumb this disease as these 
patients may benefit from adjuvant ther-
apy, including immunotherapy. Until 
now adjuvant chemotherapy has been 
CD20+ B-cells in metastatic lymph nodes 
are associated with favorable outcome in 
patients with oro- and hypopharyngeal 
carcinoma.7 On the other hand, B-cell 
infiltration detected by flowcytometry 
with CD19 were correlated with unfavor-
able outcome in metastatic ovarian car-
cinoma.8 In our material high density of 
CD20+ lymphocytes was an independent 
positive prognostic indicator. This may 
suggest that CD20+ cells in the tumor are 
including STS; CD4+ cells in the absence 
of the CD8+ cytotoxic T cells are critical 
and sufficient for NKT cell-dependent 
rejection of experimental tumors.5 In lung 
cancer the prognostic impact of CD4 is 
controversial,6 but in our material CD4+ 
cells were a positive prognostic factor in 
univariate analyses.
CD20+ cells are associated with a bet-
ter survival in lung cancer, cervical can-
cer, prostate cancer and ovarian cancer.6 
Figure 1. Disease-specific survival curves for CD3+, CD4+, CD8+, CD20+ and CD45+ lymphocytes in STS with wide resection margins.
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controversial due to inadequate selection 
criteria.
High density of CD20+ lymphocytes 
in STS with wide resection margins is an 
independent positive prognostic indicator. 
Further research to define if CD20+ cells 
can modify tumors in a way that reduces 
disease progression and metastatic poten-
tial is needed.
Materials and Methods
Patients and clinical samples. Primary 
tumor tissues from patients diagnosed 
with STS at the University Hospital of 
North Norway (UNN) from 1973 to 
2006 and the Hospitals of Arkhangelsk 
region, Russia, were used in this retro-
spective study. 249 patients were eligible 
for this study with complete medical 
records and adequate paraffin-embedded 
tissues blocks. The median follow-up was 
38 (range 0–392) months.
Tissue microarrays (TMAs) were con-
structed for high-throughput molecular 
pathology research.2 The ARIOL imaging 
system (Genetix, San Jose, CA) was used 
to scan the slides for antibody staining of 
the tissue micro arrays (TMAs).
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